RecruitingNCT06557720

Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology

Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Using Multimodal Imaging Techniques: A Prospective Observational Cohort Study

Sponsor

Xijing Hospital

Enrollment

50 participants

Start Date

Jun 11, 2024

Study Type

OBSERVATIONAL

Conditions

Magnetic Resonance Imaging Drug Resistant Epilepsy Electroencephalogram (EEG)

Summary

Using multimodal imaging technology, this study aims to explore the characteristics of epileptogenic foci in patients with drug-resistant epilepsy and identify key network nodes (such as central nodes) to provide more assistance for the diagnosis of drug-resistant epilepsy.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

Aged ≥18 years old;
Meet the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy;
Duration of epilepsy ≥2 years, with an average seizure frequency of ≥2 times per month in the 3 months prior to enrollment;
Adequate intake of two or more anti-epileptic drugs, with no intervention in the treatment plan during the trial period;
Capable of cooperating to complete treatment and related examination items; The patient and family fully understand and voluntarily sign the informed consent form.

Exclusion Criteria3

In a state of continuous epileptic seizures;
Complicated with severe infections, cerebrovascular diseases, malignant tumors, and other diseases, accompanied by severe dysfunction of the heart, liver, kidney, or other organs, or with mental disorders, or with uncorrectable hyperglycemia, or 3.patients on long-term use of corticosteroid medications;
Pregnant or lactating women; 5.Contraindications for PET, MR, EEG examinations; 6.Patients with examinations (with ferromagnetic metal implants in the body; high fever); 7.Participating in other clinical trials at the same time; 8.The patient or family withdraws the informed consent form.

Interested in this trial?

Get notified about updates and connect with the research team.